Enfuvirtid acetát (T-20)
Alias:Fuzeon
Sekvencia:CH3CO-Tyr-Thr-Ser-Leu-Ile-His-Ser-Leu-Ile-Glu-Glu-Ser-Gln-Asn-Gln-Gln-Glu-Lys-Asn-Glu-Gln-Glu-Leu-Leu- Glu-Leu-Asp-Lys-Trp-Ala-Ser-Leu-Trp-Asn-Trp-Phe-NH2
Cas č. : 159519-65-0
Molekulárny vzorec : C204H301N51064
Molekulová hmotnosť : 4492
Čistota (HPLC) : 98.0%min.
Vzhľad : Biela až sivobiela amorfná pevná látka
Jediná nečistota (HPLC) : 0.5%max
Aminokyselinové zloženie : ±10 % teoretickej hodnoty
Obsah peptidov (N %) : ≥80,0 %
Obsah vody (Karl Fischer) : ≤ 8,0 %
Obsah trifluóracetátu(HPIC) : ≤ 12,0 %
PANI (ESI) : Konzistentné
Hmotnostná bilancia : 95.0~105,0 %
stupňa : Farmaceutická trieda
Skladovanie: ZATVORENÉ, nižšie 2 ~ 8 ℃ konzervácia
Použitie : Možnosť liečby pre pacientov trpiacich HIV/AIDS.
Enfuvirtide is an antiretroviral drug used in combination therapy for the treatment of HIV-1/AIDS. It binds to the first heptad-repeat (HR1) in the gp41 subunit of the viral envelope glycoprotein and prevents the conformational changes required for the fusion of viral and cellular membranes. It works by disrupting the HIV-1 molecular machinery at the final stage of fusion with the target cell, preventing uninfected cells from becoming infected.
Enfuvirtid (INN) is an HIV fusion inhibitor, the first of a novel class of antiretroviral drugs used in combination therapy for the treatment of HIV-1 infection. It is marketed under the trade name Fuzeon (Roche).
